Molecular subtypes might affect chemotherapy-induced peripheral neuropathy in breast cancer patients receiving neoadjuvant chemotherapy
I want to congratulate Lee and colleagues for their article [1] in which they explored the incidence and riskfactors associated with chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients receiving neoadjuvant chemotherapy using docetaxel. Among the participants, 45% reported CIPN at the end of treatment. Among them, 42% reported persistent CIPN after discontinuation of treatment. Interestingly, the authors reported that pre-treatment anxiety was significantly associated with persistent CIPN.
Source: Journal of Psychosomatic Research - Category: Psychiatry & Psychology Authors: Kadri Altundag Tags: Letter to the editor Source Type: research
More News: Anxiety | Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Peripheral Neuropathy | Psychology | Taxotere